Petros Grivas· @PGrivasMDPhD · X·· 23 小时前评分70
正文 · 原文
Important data by Dr. Bedke & @AndreaNecchi in localized MIBC: periop addition of anti-PD1 not better vs neoadjuvant Gem/Cis alone; discordant with NIAGARA data. Periop EV/ICI combo has shown EFS/OS benefit from EV303/304 & VOLGA trials @myESMO #ESMOAmbassadors #ESMO26 @OncoAlert
34 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by @y_loriot 🔗 https://ow.ly/TbzF50ZZ0s2 #InsightsbyESMO在 X 查看被引用的帖子
来源：Petros Grivas · x.com